

E Shelley Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6497060/publications.pdf>

Version: 2024-02-01

123
papers

7,827
citations

109321

35
h-index

56724

83
g-index

127
all docs

127
docs citations

127
times ranked

12649
citing authors

#	ARTICLE	IF	CITATIONS
1	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	9.4	1,486
2	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	16.8	751
3	Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. <i>Cancer Cell</i> , 2019, 35, 588-602.e10.	16.8	636
4	Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. <i>Nature Medicine</i> , 2014, 20, 360-367.	30.7	353
5	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	28.9	334
6	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	28.4	303
7	A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. <i>Science Translational Medicine</i> , 2016, 8, 320ra4.	12.4	224
8	Survival after lumpectomy and mastectomy for early stage invasive breast cancer. <i>Cancer</i> , 2013, 119, 1402-1411.	4.1	216
9	The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). <i>BMJ Open</i> , 2019, 9, e026797.	1.9	182
10	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019, 121, 285-292.	6.4	168
11	Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. <i>Cell</i> , 2022, 185, 299-310.e18.	28.9	161
12	Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv263.	6.3	156
13	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Practical Radiation Oncology</i> , 2016, 6, e219-e234.	2.1	132
14	The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). <i>Annals of Surgery</i> , 2018, 268, 591-601.	4.2	125
15	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. <i>Nature Materials</i> , 2021, 20, 548-559.	27.5	125
16	Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 846-855.	0.8	113
17	Lobular breast cancer series: imaging. <i>Breast Cancer Research</i> , 2015, 17, 94.	5.0	107
18	Association of Low Nodal Positivity Rate Among Patients With <i>ERBB2</i> -Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2018, 153, 1120.	4.3	96

#	ARTICLE	IF	CITATIONS
19	Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 537-544.	4.2	89
20	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq0 0 0.5gBT /Overlock 10 T	0.5	22
21	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Annals of Surgical Oncology</i> , 2017, 24, 38-51.	1.5	80
22	Imaging-Guided Core-Needle Breast Biopsy: Impact of Meditation and Music Interventions on Patient Anxiety, Pain, and Fatigue. <i>Journal of the American College of Radiology</i> , 2016, 13, 526-534.	1.8	77
23	Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2249-2260.	1.5	77
24	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. <i>Annals of Surgical Oncology</i> , 2017, 24, 3534-3540.	1.5	76
25	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 952-960.	6.3	76
26	Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. <i>Journal of Clinical Investigation</i> , 2020, 130, 5721-5737.	8.2	73
27	The Effect of Hospital Volume on Breast Cancer Mortality. <i>Annals of Surgery</i> , 2018, 267, 375-381.	4.2	67
28	Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. <i>Annals of Surgery</i> , 2020, 271, 169-176.	4.2	65
29	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , 2016, 34, 2359-2365.	1.6	60
30	Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv372.	6.3	57
31	Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. <i>Journal of the American College of Radiology</i> , 2018, 15, 527-534.	1.8	56
32	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	1.6	52
33	Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. <i>Annals of Internal Medicine</i> , 2022, 175, 471-478.	3.9	49
34	Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ. <i>Computers in Biology and Medicine</i> , 2019, 115, 103498.	7.0	45
35	Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	4.8	44
36	Satisfaction with treatment decision-making and treatment regret among Latinas and non-Latina whites with DCIS. <i>Patient Education and Counseling</i> , 2014, 94, 83-89.	2.2	36

#	ARTICLE	IF	CITATIONS
37	DCIS with Microinvasion: Is It In Situ or Invasive Disease?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3124-3132.	1.5	36
38	Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 227-235.	2.5	34
39	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , 2016, 2, 16007.	5.2	33
40	Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. <i>Annals of Surgical Oncology</i> , 2020, 27, 2600-2613.	1.5	31
41	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. <i>Modern Pathology</i> , 2019, 32, 1257-1262.	5.5	27
42	Matrix compliance permits NF- κ B activation to drive therapy resistance in breast cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
43	Association of Smartphone Ownership and Internet Use With Markers of Health Literacy and Access: Cross-sectional Survey Study of Perspectives From Project PLACE (Population Level Approaches to Tj ETQq1 1 0.7843 14 rgBT7/Overlo	1.5	27
44	Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e283-e290.	2.5	24
45	Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2890-2898.	1.5	24
46	Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Managementâ€”American Society of Breast Surgeons Opioid/Pain Control Workgroup. <i>Annals of Surgical Oncology</i> , 2020, 27, 985-990.	1.5	23
47	Incidence of Ductal Carcinoma <i>In Situ</i> in the United States, 2000â€”2014. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1316-1323.	2.5	22
48	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	1.5	22
49	Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017, 24, 660-668.	1.5	21
50	Patientâ€”reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. <i>Cancer</i> , 2021, 127, 757-768.	4.1	21
51	Anatomy and Breast Cancer Staging. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 51-67.	1.5	20
52	Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3141-3151.	1.5	20
53	Unmasking the immune microecology of ductal carcinoma in situ with deep learning. <i>Npj Breast Cancer</i> , 2021, 7, 19.	5.2	20
54	Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring. <i>Annals of Surgical Oncology</i> , 2016, 23, 4134-4136.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?. Journal of Magnetic Resonance Imaging, 2017, 46, 1332-1340.	3.4	19
56	Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. Radiology, 2019, 292, 77-83.	7.3	19
57	Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women With Breast Cancer. JCO Oncology Practice, 2022, 18, e827-e838.	2.9	19
58	Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?. Academic Radiology, 2017, 24, 1139-1147.	2.5	18
59	Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial 20011. Annals of Surgical Oncology, 2017, 24, 3559-3566.	1.5	18
60	A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients. JNCI Cancer Spectrum, 2020, 4, pkz103.	2.9	17
61	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Research and Treatment, 2020, 180, 207-217.	2.5	17
62	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features. Radiology, 2022, 303, 54-62.	7.3	17
63	Reframing the conversation about contralateral prophylactic mastectomy: Preparing women for postsurgical realities. Psycho-Oncology, 2019, 28, 394-400.	2.3	15
64	The Evolution of Breast Satisfaction and Well-Being after Breast Cancer: A Propensity-Matched Comparison to the Norm. Plastic and Reconstructive Surgery, 2020, 145, 595-604.	1.4	15
65	A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	15
66	Can Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy?. Journal of the American College of Surgeons, 2016, 223, 279-285.	0.5	14
67	Mobile Health Application for Patients Undergoing Breast Cancer Surgery: Feasibility Study. JCO Oncology Practice, 2021, 17, e1344-e1353.	2.9	14
68	Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors. European Radiology, 2017, 27, 2275-2281.	4.5	13
69	The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. Annals of Surgical Oncology, 2018, 25, 2807-2812.	1.5	13
70	Clinical and pathological stage discordance among 433,514 breast cancer patients. American Journal of Surgery, 2019, 218, 669-676.	1.8	13
71	Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. International Journal of Radiation Oncology Biology Physics, 2020, 106, 377-389.	0.8	13
72	Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. Annals of Surgical Oncology, 2021, 28, 5544-5552.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Decreasing rates of axillary lymph node dissections over time: Implications for surgical resident exposure and operative skills development. <i>American Journal of Surgery</i> , 2019, 218, 786-791.	1.8	12
74	Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. <i>American Journal of Epidemiology</i> , 2019, 188, 197-205.	3.4	12
75	Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 661-670.	2.5	12
76	Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer. <i>Journal of Surgical Oncology</i> , 2015, 111, 931-934.	1.7	11
77	Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ. <i>Academic Radiology</i> , 2017, 24, 1364-1371.	2.5	11
78	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	5.1	11
79	The effect of treatment on patient-reported distress after breast cancer diagnosis. <i>Cancer</i> , 2019, 125, 3040-3049.	4.1	10
80	Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 7441-7449.	1.5	10
81	Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway with enrolment shortfalls to identify previously hidden barriers and improve recruitment. <i>Trials</i> , 2022, 23, 258.	1.6	10
82	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
83	It's not you, it's me: The influence of patient and surgeon gender on patient satisfaction scores. <i>American Journal of Surgery</i> , 2020, 220, 1179-1188.	1.8	9
84	Outcomes and Costs for Women After Breast Cancer: Preparing for Improved Survivorship of Medicare Beneficiaries. <i>JCO Oncology Practice</i> , 2021, 17, e469-e478.	2.9	8
85	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates. <i>Npj Breast Cancer</i> , 2021, 7, 85.	5.2	8
86	Derivation of a nuclear heterogeneity image index to grade DCIS. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 4063-4070.	4.1	8
87	Patterns of Breast Magnetic Resonance Imaging Use. <i>JAMA Internal Medicine</i> , 2014, 174, 122.	5.1	7
88	Surgery for Men with Breast Cancer: Do the Same Data Still Apply?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4720-4729.	1.5	7
89	Surgical Management of the Axilla in Elderly Women With Node-Positive Breast Cancer. <i>Journal of Surgical Research</i> , 2020, 254, 275-285.	1.6	7
90	Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. <i>American Journal of Roentgenology</i> , 2021, 216, 903-911.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Contemporary management of ductal carcinoma in situ and lobular carcinoma in situ. <i>Chinese Clinical Oncology</i> , 2016, 5, 32-32.	1.2	7
92	Metastatic breast cancer: Who benefits from surgery?. <i>American Journal of Surgery</i> , 2022, 223, 81-93.	1.8	6
93	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , 2021, 125, 1443-1449.	6.4	6
94	“œIs it cancer or not?”—A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. <i>Cancer</i> , 2022, 128, 1676-1683.	4.1	6
95	The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions. <i>Journal of Surgical Research</i> , 2019, 241, 188-198.	1.6	5
96	A medicare-based comparative mortality analysis of active surveillance in older women with DCIS. <i>Npj Breast Cancer</i> , 2020, 6, 57.	5.2	5
97	A multi-modal exploration of heterogeneous physicochemical properties of DCIS breast microcalcifications. <i>Analyst</i> , 2022, 147, 1641-1654.	3.5	5
98	Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression. <i>Matrix Biology Plus</i> , 2022, 14, 100105.	3.5	5
99	Predicting Upstaging of DCIS to Invasive Disease: Radiologists' Predictive Performance. <i>Academic Radiology</i> , 2020, 27, 1580-1585.	2.5	4
100	Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. <i>JCO Oncology Practice</i> , 2021, 17, e1639-e1648.	2.9	4
101	A new method to accurately identify single nucleotide variants using small FFPE breast samples. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	4
102	Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery: How Low is “œLow Risk”?. <i>Annals of Surgical Oncology</i> , 2021, 28, 5758-5767.	1.5	4
103	Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. <i>Cancer</i> , 2013, 119, 3254-3255.	4.1	3
104	The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 3412-3417.	1.5	3
105	Fat Grafting—More Than Just the Hype. <i>JAMA Surgery</i> , 2017, 152, 951.	4.3	3
106	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. <i>JAMA Oncology</i> , 2020, 6, 1117.	7.1	3
107	Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women. <i>Cancer</i> , 2021, 127, 2515-2524.	4.1	3
108	Reoperation for Margins After Breast Conservation Surgery. <i>JAMA Surgery</i> , 2016, 151, 656.	4.3	2

#	ARTICLE	IF	CITATIONS
109	Contralateral Prophylactic Mastectomy. JAMA Surgery, 2017, 152, 282.	4.3	2
110	How Low Can We Go and Should We? Risk Reduction for Minimal-Volume DCIS. Annals of Surgical Oncology, 2018, 25, 354-355.	1.5	2
111	Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity?. Journal of Surgical Research, 2020, 255, 205-215.	1.6	2
112	Editorial: What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?. Journal of the National Cancer Institute, 2017, 109, .	6.3	1
113	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. Cancer, 2020, 126, 5239-5246.	4.1	1
114	ASO Visual Abstract: Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery How Low is Low Risk?. Annals of Surgical Oncology, 2021, 28, 645-645.	1.5	1
115	Reframing treatment for ductal carcinoma in situ: could less be more?. Bulletin of the American College of Surgeons, 2012, 97, 50-1.	0.3	1
116	Automated Dcis Identification From Multiplex Immunohistochemistry Using Generative Adversarial Networks. , 2022, , .		1
117	New Treatment Paradigms for Patients with Ductal Carcinoma In Situ. Current Breast Cancer Reports, 2013, 5, 86-98.	1.0	0
118	Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?. Current Breast Cancer Reports, 2019, 11, 190-202.	1.0	0
119	Response to Habel and Buist. Journal of the National Cancer Institute, 2020, 112, 216-217.	6.3	0
120	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals of Surgical Oncology, 2021, 28, 436-437.	1.5	0
121	ASO Visual Abstract: Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. Annals of Surgical Oncology, 2021, 28, 524.	1.5	0
122	ASO Visual Abstract: Contralateral Axillary Nodal Metastases Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. Annals of Surgical Oncology, 2021, 28, 608-609.	1.5	0
123	More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk. Journal of Clinical Oncology, 2022, , JCO2102733.	1.6	0